

Published in final edited form as:

Nat Genet. ; 44(5): 502–510. doi:10.1038/ng.2205.

GENETICS OF GENE EXPRESSION IN PRIMARY IMMUNE CELLS IDENTIFIES CELL-SPECIFIC MASTER REGULATORS AND ROLES OF HLA ALLELES

Benjamin P Fairfax¹, Seiko Makino¹, Jayachandran Radhakrishnan¹, Katharine Plant¹, Stephen Leslie², Alexander Dilthey³, Peter Ellis⁴, Cordelia Langford⁴, Fredrik O Vannberg¹, and Julian C Knight¹

¹Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford, OX3 7BN, UK

²Department of Oncology, University of Oxford, Oxford, UK

³Department of Statistics, University of Oxford, Oxford, UK

⁴Wellcome Trust Sanger Institute, University of Cambridge

Abstract

Trans-acting genetic variants play a substantial, albeit poorly characterized, role in the heritable determination of gene expression. Using paired purified primary monocytes and B-cells we identify novel, predominantly cell-specific, cis- and trans-eQTL (expression quantitative trait loci). These include multi-locus trans-associations to *LYZ* in monocytes and to *KLF4* in B-cells. Additionally, we observe B-cell specific trans-association of rs11171739 at 12q13.2, a known autoimmune disease locus, to *IP6K2* ($p_{\text{B-cell}}=5.8\times 10^{-15}$), *PRIC285* ($p_{\text{B-cell}}=3.0\times 10^{-10}$) and an upstream region of *CDKN1A* ($p_{\text{B-cell}}=2\times 10^{-52}$; $p_{\text{monocyte}}=1.8\times 10^{-4}$), suggesting roles for cell cycle regulation and PPAR γ signaling in disease pathogenesis. We also find specific HLA alleles forming trans-association with the expression of *AOAH* and *ARHGAP24* in monocytes but not in B-cells. In summary, we demonstrate that mapping gene expression in defined primary cell populations identifies new cell-specific trans-regulated networks and provides insights into the genetic basis of disease susceptibility.

Correspondence to: Benjamin Fairfax, Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford, OX3 7BN UK, Tel: +44 1865 287531, Fax +44 1865 287533. bfairfax@well.ox.ac.uk; and Julian Knight, Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford, OX3 7BN UK, Tel: +44 1865 287651, Fax +44 1865 287533, julian@well.ox.ac.uk.

AUTHOR CONTRIBUTIONS Author contributions are listed in alphabetical order. B.P.F. and J.C.K. conceived, designed and initiated the study. B.P.F., J.C.K., K.P. and S.M. established the volunteer cohort and sample collection. B.P.F., K.P., P.E. and S.M. performed the experimental work. B.P.F., J.C.K., J.R. and S.M. analysed the data. C.L., F.O.V. and S.L. contributed reagents and expertise. A.D. and S.L. performed the HLA imputation. B.P.F. and J.C.K. wrote the paper with contributions to manuscript editing from other authors. All authors read and approved the manuscript before submission.

URLs. Catalog of Published Genome-Wide Association Studies (www.genome.gov/GWA_studies)

European Genome-Phenome Archive (EGA) (www.ebi.ac.uk/ega/)

The R Project for Statistical Computing (<http://www.r-project.org/>)

Array Express (<http://www.ebi.ac.uk/arrayexpress/>)

ACCESSION NUMBERS: Gene expression data is available through ArrayExpress under accession number E-MTAB-945. Genotyping data has been deposited at the European Genome-Phenome Archive (EGA) and is available on request.

COMPETING FINANCIAL INTERESTS The authors declare no competing financial interests.

INTRODUCTION

Defining the genetic determinants of gene expression is crucial to understanding the biological and medical significance of genetic variation. This has particular relevance in the drive to identify functional variants underlying observed disease associations from genome-wide association studies (GWAS)¹. It is increasingly apparent that functional activity of many genetic polymorphisms is dependent upon context, requiring the study of relevant cell or tissue types in a particular biological state²⁻⁴. This context-specificity means that whilst lymphoblastoid cell lines (LCLs) and other tissues have provided important insights, they may fail to capture the *in vivo* activity of particular variants in disease relevant tissues^{5,6}. Recent cell and tissue specific studies highlight the importance of context in the identification of expression associated genetic variants^{3,4,7-10}. In umbilical cord-derived cultured cells, up to 80% of regulatory variants act in a cell-type specific manner³, whilst comparison of skin, fat and LCLs identify only 30% of eQTLs to be common between tissues⁴. The basis for this specificity remains unresolved, but may relate to variation at tissue specific distal enhancers as opposed to conserved promoter elements³. Analyses performed on non-cultured primary tissue have typically used sources with a heterogeneous cell composition, such as peripheral blood mononuclear cells (PBMCs)^{3,11} or fat⁴. Whilst this provides general insights into tissue specific eQTLs, highly cell-type specific eQTLs may be missed due to signal saturation from other cell types where the eQTL is absent. This is especially pertinent in the elucidation of trans-acting eQTLs, where tissue specificity appears to be of increased relevance¹².

Here we sought to determine physiologically active cell type-specific eQTLs of high relevance to immunity and inflammation in paired samples of monocytes and B-cells, freshly purified by positive selection. Our analysis highlights both the extent of eQTL cellular specificity, especially for trans-acting variants, and the underlying inherent complexity of eQTL action. We observe multiple examples of genes with eQTL in both cell types but to different loci, and of eQTL showing opposing cell-type dependent directional effects. Mapping genetic determinants of gene expression in these immune cell types is shown to be highly informative for reported GWAS hits, notably involving immune, infectious and inflammatory disease.

RESULTS

Defining eQTLs in purified B-cell and monocyte populations

B-cells are lymphocytes with crucial roles in adaptive and humoral immunity whilst monocytes form an innate myeloid derived cell population that initiates an inflammatory, cytokine mediated response upon microorganism invasion. Their divergent functions and origins ensure these cell populations form highly informative primary tissue for insight into immune and inflammatory diseases. Furthermore, whereas multiple LCL eQTL analyses have been performed, as yet there are no large studies focused on B-cells, the cells immortalized to derive LCLs. To investigate eQTLs in these primary cell types we used positive selection, a method demonstrated to result in superior cell purity for microarray analysis¹³ to separate CD19⁺ B-cells and CD14⁺ monocytes from PBMCs prepared using the whole blood of 288 healthy European volunteers (Online methods). Purity of samples was confirmed with flow cytometry and was 90-95% for B-cells and approaching 99% for monocytes. Genome-wide gene expression profiling and genotyping was performed using HumanHT-12 v4 BeadChips (Illumina) and HumanOmniExpress-12v1.0 BeadChips (Illumina). Following processing and quality control we performed eQTL mapping at 651210 markers for each of 283 individuals.

Cell-specific cis-eQTL are common, complex and directional in effects

Identification of locally acting eQTL (referred to here as cis-acting) was performed by testing SNPs that fell within a 2.5Mb interval either side of the probe for association with expression in each cell type using linear and Spearman rank models. In this large, highly purified paired sample set we found little difference between the significance values using either approach - however, only eQTL that reached a permuted $p < 1 \times 10^{-3}$ in both analyses were carried forward. We identified 82,346 eQTL (SNP-probe interactions, referred to hereafter as eSNPs) at permuted $p < 0.001$, 32.2% of which were unique to B-cells, 45.9% to monocytes and 21.8% shared between cell types (Figure 1, Supplementary Figure 1, Supplementary Tables 1-2). This corresponded to 7468, 6831 and 1323 genes (8441, 7589 and 1466 probes) in which there was at least one cis-eSNP with permuted $p < 0.001$ specific to B-cells, monocytes and shared by both cell types, respectively (a full description of associations at different significance thresholds is given in Supplementary Table 3). Comparative analysis of this dataset demonstrated a high concordance of eSNPs identified here that were shared between cell types and those previously identified in primary cell eQTL analysis^{10,14}. This degree of commonality was not so clearly demonstrable upon analysis of LCLs¹⁵, possibly reflective of intrinsic differences between primary and cultured cells (Supplementary Figure 2). Cell specific eSNPs may exist secondary to cell-specific function of genetic variants, or alternatively when transcript expression is restricted to one cell type only. In order to identify eSNPs formed due to cell specific functional variants we defined genes expressed at similar levels across cell types but which demonstrated robust cell-specific effects. Even after excluding genes whose mean log₂ expression across the cohort differed in magnitude by >0.5 between cell types, we identified 70149 cis-eSNPs in almost identical proportions by cell type. In general, whilst cell-specific eQTLs were observed more frequently, they tended to have smaller effect sizes than those shared between cells (median r^2 5.1%, 5.5% and 9.8% for B-cell-specific, monocyte-specific and shared respectively) with 54, 107 and 351 eSNPs explaining more than 50% of the variance in expression of 14, 37 and 61 genes respectively. Using further RNA purified from randomly selected individuals within the cohort we were able to replicate the cellular specificity for selected genes by real-time PCR ($n=14-29$ homozygous individuals per gene) (Supplementary Figure 3). When RNA from crude PBMCs from the same individuals was analysed however, the signal was frequently absent (Supplementary Figure 3b,d,i), supporting the importance of cell purification in the identification of subtle primary cell-specific eQTL.

Consistent with other reported eQTL analyses, we find the effect size and statistical significance of an eQTL varies as a function of distance from transcription start site (TSS) (Supplementary Figure 4). Notably, the density distribution of eSNPs demonstrating cell-specific effects on expression was more dispersed around the TSS in comparison to that of shared eQTL. This supports the premise that cell specific eQTL are enriched in more distant enhancer elements involved in cell-specific expression³.

Previously reported eQTL shared between cell types have the same directional effect³. Whilst in general this holds true for our analysis of primary monocytes and B-cells, we observe several eQTL with cell type-dependent directional effects: the same eSNP being associated with opposing directional effects. We identified 197 eSNPs in 35 genes demonstrating significant 'directional eQTL' in B-cells and monocytes (permuted $p < 0.001$ both cell types, total opposing directional effect >0.5 in terms of magnitude of mean log₂ expression difference between major and minor alleles) (Figure 2a, Supplementary Table 4). To further investigate the significance of these directional findings we estimated the differences in the slopes using z-scores and demonstrated that for 31 of the 35 genes the differences were highly significant (Bonferroni corrected $p < 1 \times 10^{-38}$) (Supplementary Table 4), thus strongly suggesting these were not chance observations. The most significant

directional eQTL were noted to the gene *DFNA5*, previously implicated in familial deafness¹⁶ and a target of promoter methylation in gastric cancer¹⁷. Other notable genes with directional effect include *MCOLN2*, encoding a cation channel involved in type I interferon responses¹⁸, and *SELL* (also known as L-selectin, CD62L). The latter is of particular interest given the role of this cell surface receptor in monocyte recruitment to lymphoid tissues during inflammation¹⁹ and previous association of this region with amyotrophic lateral sclerosis²⁰. We did not observe the reported association with *KIFAP3* expression in LCLs²⁰ but note the disease associated variants show a cell directional effect with the neighboring gene *SELL*. Real-time PCR quantification of *DFNA5* and *SELL* on further RNA purified from randomly selected homozygous individuals (*DFNA5* n=16; *SELL* n=20-28) confirmed these directional effects were not a product of array-mediated artifact (Supplementary Figure 3h,i).

The extent to which a particular genetic variant may demonstrate diverging effects according to cell type is unclear. Here we find many variants show multiple, cell specific actions, with 6.4% of cell specific eSNPs additionally forming eQTL to different genes in the alternative cell type (Supplementary Figure 5a). For example rs738289 and linked eSNPs in the first intron of *MGAT3*, a gene encoding a glycosyltransferase²¹, showed association with *MGAT3* in B-cells ($p=9.8 \times 10^{-26}$); by contrast in monocytes this eSNP was solely associated with the neighboring gene *SYNGR1* encoding expression of vesicle associated protein ($p=1.2 \times 10^{-17}$) (Figure 2c). Just as cell type may define the gene a particular variant regulates, we observe certain genes whose expression is modulated by different variants in a cell specific manner. Such examples include *TSPAN3* (Supplementary Figure 5b) and *AKAP7* (not shown), in keeping with the effect of regulatory genetic variants being dependent on the environment defined by the cell type.

Identification of multiple cell-specific trans-associated eQTL

Although a considerable element of heritable gene expression is proposed to act in trans, trans-eQTL have proved difficult to define in the cell populations studied to date. It is probable that trans-acting variants are involved in a more multifactorial process than those acting in cis, reflecting contributions both of prevailing environmental cues and the cellular context. We explored this question in each of our primary cell populations and mapped trans associated eSNPs using a conservative significance threshold of 1×10^{-11} , based on a Bonferonni correction given the number of SNPs analysed. For autosomal genes and SNPs, we identified 1704 eSNPs involving 75 genes specific to B-cells, 101 to monocytes and 19 shared (Figure 1, Supplementary Table 2). It is increasingly apparent that particular variants act as master regulators of transcription as trans-eQTL^{12,14}. Many of these eSNPs form cis-eQTL to genes that probably define the nodal gene of these subsets (Supplementary Table 2, Supplementary Figure 6) and we observe two highly cell specific examples in the form of *KLF4* (Supplementary Figures 7,8) and *LYZ* (discussed below). We found that only 7% of trans-eSNPs are shared between cell types, implying trans-eQTLs show a greater degree of cell specificity than cis-eQTLs. Given that B-cells constitute ~5% of PBMCs and monocytes 10-15%¹³, cell specific traits will often be undetectable in eQTL analysis of a heterogeneous population of PBMCs due to saturation of cell specific signals by expression signatures from other cell types.

LYZ as a monocyte-specific master regulator of a large gene set

Monocytes have evolved to scavenge and present antigens through a highly conserved endosomal pathway. This is assisted via the release of hydrolyzing enzymes from secretory granules. Lysozyme forms a key component of monocyte secretory granules and degrades bacterial cell wall derived peptidoglycan. We find evidence of a novel master regulatory region involving cis- and trans-eQTL at the 12q15 locus for rs10784774 and associated

eSNPs spanning *LYZ*, encoding lysozyme (Figure 3). This locus forms a monocyte specific cis-eQTL (Supplementary Figure 9) to a probe mapping to the 3' UTR of *LYZ* ($p_{\text{monocyte}}=8.9\times 10^{-78}$) and forms a trans eQTL to a remarkable 62 annotated genes (72 probes) throughout the genome at a $p<1\times 10^{-11}$, the most significant association being to the gene *CREB1* ($p_{\text{monocyte}}=2.03\times 10^{-67}$) and many others at a lower significance (Figure 3, Supplementary Figure 10 and Supplementary Table 5). Interrogation of a previously published primary cell eQTL analyses of negatively selected monocytes from whole blood¹⁰ and whole blood RNA from a mixed disease and control cohort¹⁴ replicates this strong association between 12q15 and expression of both *LYZ* and *CREB1* (*CREB1*, $p=5.1\times 10^{-22}$ (rs11177644) monocytes¹⁰; $p=3.2\times 10^{-67}$ (rs2168029) whole blood¹⁴). The multi-faceted transcriptional properties of CREB1 in immune cells²² ensure it is a highly plausible candidate to regulate expression of many downstream genes, consistent with recent reports of other transcription factors underlying multiple eQTL to one locus¹². Of note, *LYZ* expression was most strongly correlated to that of *CREB1* ($r^2=0.82$, $p=5.7\times 10^{-107}$) and *CREB1* expression was highly correlated with the majority of trans-associated genes to this locus (Supplementary Table 5). This would support a pathway whereby cis-modulation of *LYZ* results in differential expression of *CREB1*, possibly through downstream effects via altered lysozyme secretion, with resultant modulation of a network of trans-associated genes.

We noted a weaker cis-eQTL for rs10784774 with *YEATS4* expression in both cell types ($p_{\text{monocyte}}=1.26\times 10^{-13}$, $p_{\text{B-cell}}=1.55\times 10^{-7}$). Although *YEATS4* is a transcription factor²³ and therefore could potentially account for the observed trans-eQTL, the exclusivity of the trans-eQTL to monocytes would argue against this. Furthermore, correlation analyses between monocyte *YEATS4*, *CREB1* and *LYZ* expression and that of other probes demonstrates the strongest coefficient of correlation to expression of *LYZ* and *CREB1* for all trans associated genes to this locus (Supplementary Table 5).

Imputation demonstrates that rs10784774 forms the 5' SNP in a haplotype spanning *LYZ* of 4 SNPs in almost complete LD (Supplementary Figure 11). Analysis of ENCODE ChIP-seq data²⁴ demonstrates a p300 binding site overlapping rs10784774 and further sites overlapping the promoter (Supplementary Figure 12). To investigate the allelic relationship between p300 and *LYZ* expression, genotype conditioned correlation analysis between basal expression of p300 and *LYZ* was performed. We observed a strong inverse correlation between expression of p300 and *LYZ* expression in individuals homozygous with the ancestral A allele at rs10784774 but no association with expression in the homozygous G allele (AA: r^2 0.41, $p=4.4\times 10^{-8}$; AG: r^2 0.22, $p=1.4\times 10^{-9}$; GG: r^2 0.02, $p=0.11$), supportive of allele-specific regulation of *LYZ* via p300.

Trans-eQTL for the disease-associated 12q13.2 locus with cell cycle regulators

The generation of self-reactive auto-antibodies is a characteristic feature of autoimmune disease. To prevent this, B-cells expressing self-reactive antibody are removed prior to maturation to antibody secreting plasma cells. Here we show SNPs at 12q13.2, a locus showing reproducible association with multiple autoimmune diseases including type I diabetes (T1D)²⁵⁻²⁸ regulate the expression of genes implicated in cell-cycle control in trans in B-cells only. Previous studies have demonstrated rs11171739 at 12q13.2 forms a cis-eQTL involving *RPS26* in liver⁸, LCLs¹⁵ and leukocytes¹¹. Differential *RPS26* expression however appears unable to explain susceptibility to T1D at this locus²⁹ and the causal genes are unresolved. We find a highly significant trans-eQTL in B-cells with *IP6K2* (encoding inositol hexakisphosphate kinase-2) ($p_{\text{B-cell}}=5.8\times 10^{-15}$) (Figure 4a). *IP6K2* is required for p53-mediated apoptosis³⁰ and is able to regulate the accumulation of p21/CIP1, a protein involved in cell division, apoptosis of pathogenic memory B-cells³¹ and is a known susceptibility gene for SLE³². Intriguingly, a further trans-association was found for a

transcript mapping 5' to the actual gene encoding p21/CIP1 (*CDKN1A*) ($p_{B-cell}=2\times 10^{-52}$, $p_{monocyte}=1.8\times 10^{-4}$). This region is denoted as the pseudogene *LAP3P2* but we find using RNA-seq it is a region of high transcriptional activity in primary B-cells (Figure 4c). rs11171739 has also been associated with type 2 diabetes (T2D)³³ and we note on further analysis of this region a trans eQTL between this SNP and *PRIC285* ($p_{B-cell}=3.0\times 10^{-10}$) a transcriptional coactivator involved in PPAR γ signaling. Given the role of PPAR γ agonists in T2D management this association may be of notable biological relevance³⁴.

Disease associated HLA alleles underlie trans-associations to the MHC

HLA genes play a critical role in the processing and presentation of antigens, they are highly polymorphic and show robust association with disease but the functional basis of this remains unresolved. Here we describe several striking associations to the MHC region ($p<1\times 10^{-11}$), segregating by *HLA* allele, which may provide insights into the basis of associations with ulcerative colitis, rheumatoid arthritis and T1D. We describe a trans-association of *AOAH*, encoding acyloxyacyl hydrolase lipase that degrades bacterially derived lipopolysaccharide³⁵, to the MHC class II region. An association between the MHC and *AOAH* has recently been described in a study of whole blood RNA from a mixed population of disease and control cohorts (peak eSNP rs2395185, 7.0×10^{-38})¹⁴. We replicate this finding at this SNP (rs2395185 $p_{monocyte}=5.7\times 10^{-39}$), with the most strongly associated eSNP in our dataset being rs28366298 ($p_{monocyte}=1.6\times 10^{-43}$). Notably, we find only very weak association of this region in B-cells ($p_{B-cell}>1\times 10^{-3}$) (Figure 5a), suggesting much of the signal in whole blood studies is monocyte derived, and providing underlying potential mechanistic insight. To further define this trans-association we inferred the underlying *HLA* alleles to 2 and 4 digit resolution in all individuals through genotype imputation^{36,37}. This enables us to refine the association of *AOAH* expression and the MHC to the presence or absence of *HLA* class II alleles DRB1*04, *07 and *09 ($p<2.2\times 10^{-16}$, 2 way ANOVA) which define *HLA-DRB4* (Figure 5b, Supplementary Figure 13). Specifically, individuals homozygous for any of these alleles express 0.6 fold (95% C.I. 0.57-0.67) the level of *AOAH* as individuals homozygous for all other alleles at DRB1. Interestingly we observe a second monocyte-specific trans-association for DRB1*04/*07/*09 to *ARHGAP24* (peak eSNP rs28366298 $p_{monocyte}=4.59\times 10^{-14}$). *ARHGAP24* encodes a negative regulator of Rho-GTPase activating protein implicated in cell migration³⁸. Converse to *AOAH*, we observe that individuals homozygous for DRB1*04/*07/*09 alleles express 1.4 fold (95% C.I. 1.30-1.54) the level of *ARHGAP24* than all other alleles. These alleles are associated with autoimmune disease susceptibility, as is *HLA-DRB4* (defining the DR53 antigen)^{39,40}. Our study shows that specifically monocytes from individuals with *HLA-DRB4* have significantly reduced *AOAH* expression, a protein with anti-inflammatory properties, in tandem with increased expression of *ARHGAP24*.

Common to both cell types, we observed a trans-eQTL to *DEF8* (rs2760985 $p_{monocyte}=9\times 10^{-17}$ $p_{B-cell}=6.2\times 10^{-13}$) (Figure 5c), a chromosome 16 encoded gene expressed in peripheral blood mononuclear cells of unknown function⁴¹. This association resolves to presence of the DQA1*0301 allele. These novel trans-associations to class II MHC alleles represent the first observations of differential expression of genes defined in trans by the presence of specific *HLA* alleles. Whilst it is unclear whether these molecular signatures are causative or arising from the disease risk associated *HLA* alleles, these trans-associations provide original insight into the mechanistic basis of the MHC and disease susceptibility.

Finally, although *HLA* allele carriage is associated with haplotype specific expression patterns across the MHC⁴², the high density of SNPs across this region, especially within classical *HLA* genes, results in exclusion of many probes. For *HLA-C*, an eQTL has been reported for a SNP rs9264942⁴³ located 35kb upstream of the gene associated with HIV-1

viral load and AIDS progression^{43,44}. Our array data suggests a significant cis-eQTL, common to both cell types, but is potentially confounded by SNPs in the probe sequence. To overcome this we performed quantitative RT-PCR across the cohort using primers to regions with minimal SNP density and discrete from the probe binding site. This demonstrated a significant eQTL for rs9264942 ($p=7.4\times 10^{-9}$) in PBMCs consistent with previous findings⁴³ but the most significant association for *HLA-C* mapped to rs10484554 ($p=5.2\times 10^{-16}$) (Supplementary Figure 14a), a GWAS SNP showing highly significant association with AIDS progression⁴⁵ and psoriasis^{46,47}. HLA imputation analysis shows the cis-eQTL can be defined in terms of presence of *HLA* alleles C*0602 and C*1203 (Supplementary Figure 14b,c). Further investigation is required to resolve the role of HLA-C and genetic variation at this locus in terms of disease susceptibility. C*0602 has been strongly implicated in susceptibility to psoriasis⁴⁸, while current evidence shows that the association with HIV control and progression is more complex, with HLA-B mediated peptide presentation playing a key role⁴⁹.

Informativeness of cell-specific eQTL analysis for fine mapping and functional characterisation of GWAS

Understanding the functional impact of genetic markers of susceptibility to disease is of central importance in determining mechanisms of pathogenesis^{1,50}. Whilst disease susceptibility loci can be associated with differential gene expression, just as with eQTL in general, this effect may be cell-specific. It is also probable many disease-associated eQTL only manifest under physiological conditions of mixed cell populations permitting appropriate cellular interactions and antigen exposure. We hypothesized that analysis of primary B-cells and monocytes freshly isolated from peripheral blood may identify such eQTL with the attractive promise of delineating functional activity to the innate or adaptive arms of the immune response. We investigated eQTLs involving SNP markers identified as a disease risk alleles at genome-wide significance ($p < 5\times 10^{-8}$) for 548 common traits listed in the Catalog of Published Genome-Wide Association Studies (10th September 2011). We find that 49.4% of traits (17.3% of reported GWAS SNPs) are associated with one or more significant cis-eQTL based on the listed GWAS markers or identified proxy SNPs from the 1000 Genomes Project (CEU cohort, $r^2 > 0.8$). A complete integrated dataset indexed by trait is provided (Supplementary Table 6). Overall, we find that 730 genes show significant cis-eQTL related to GWAS, of which 33.5% are B-cell-specific, 45.5% are monocyte-specific and 21% are found in both cell types.

It remains a possibility that GWAS SNPs have divergent effects between cell types. In support of this we find 4.6% of reported GWAS SNPs have cis-eQTL to differing genes in a cell type dependent manner. For example, rs10781500, a SNP associated with ulcerative colitis⁵¹ and ankylosing spondylitis⁵² shows contrasting cis-eQTL for three genes at 9q34.3 dependent on cell type. In B-cells the SNP associates with expression of the small nuclear RNA activating complex polypeptide gene *SNAPC4* ($p=3.1\times 10^{-5}$) while in monocytes the association is with *SDCCAG3* ($p=1.9\times 10^{-12}$) and *CARD9* ($p=1.0\times 10^{-24}$); *SDCCAG3* is a poorly characterised gene encoding a molecule implicated in presentation of TNF receptor 1 on the cell surface⁵³ while *CARD9* encodes a caspase recruitment domain-containing signaling protein with a regulatory role in innate immunity and apoptosis⁵⁴. Our analysis of highly purified primary cell populations also highlights that certain traits demonstrate a preponderance of cell specific eQTL, as illustrated by systemic lupus erythematosus (SLE) for B-cells, while others traits show a predominance of monocyte-specific eQTL, as seen in ulcerative colitis (UC) (Figure 6). These diseases have contrasting and complex etiologies involving adaptive and innate immunity, the role of B-cells and autoantibody production being paramount in SLE, while in UC innate immunity involving dysregulated mucosal immunity and monocyte lineage cells are critically important. Our analysis defines a catalog

of genes showing cell-specific or shared cis-eQTL for genetic variants implicated in many common diseases (Figure 6) (Supplementary Figure 15, Supplementary Table 6), facilitating the fine mapping and functional characterisation of specific genes and variants within GWAS disease intervals.

DISCUSSION

In this study we illustrate that eQTL analysis of expression data obtained from highly purified primary cells enriches eQTL identification and reveals underlying cellular specific complexity not appreciable from mixed tissue. It is clear that whilst many eQTL with large effect sizes are shared across cells, the majority of eQTL in primary tissue are cell-specific. The degree to which a single variant can associate with the expression of different genes in monocytes and B-cells is particularly striking. It is probable that analysis of further divergent primary cell populations will increase the number of examples of such cell-specific eQTL. The delineation of cell-directional eQTLs is also of importance; in the case of those observed with *SELL*, which encodes a membrane protein involved in cellular recruitment to areas of inflammation, the intriguing possibility is raised that a polymorphism may influence the predominant cell subset recruited.

This study reveals trans-eQTLs possess an even higher degree of cellular autonomy than cis, reflecting them manifesting as products of upstream gene expression and cellular cross-talk. Notably, we identify novel master-regulatory regions specific to monocytes via *LYZ* and B-cells via the expression of *KLF4*. The functional implications with respect to infectious disease susceptibility of the multi-locus *LYZ* eQTL remain to be explored, but the existence of several genes including *ERAP2*, encoding an aminopeptidase involved in the loading of class I MHC molecules⁵⁵ as well as *RAB27A*, encoding a GTPase critical to the membranous tethering of secretory lysosomes⁵⁶, would suggest this eQTL may impact upon antigen presentation. The identification of B-cell specific trans-eQTLs to rs11717139, a locus with reproducible association to autoimmune diseases, in genes with putative roles in cell-cycle and apoptosis provides novel candidate genes for analysis in autoimmune disease susceptibility. B-cells are intrinsically prone to apoptosis providing protection against the generation of self-reactive antibodies. Regulation of genes involved in apoptosis would therefore be predicted to alter this process and predispose to autoimmunity⁵⁷. It is notable that these genes do not have strong cis-eQTLs which otherwise might be expected to be disease associated.

Finally, we demonstrate for the first time the possession of specific *HLA* alleles regulates gene expression in trans in a cell specific manner. The monocyte specific trans association of *AOAH* and *ARHGAP24* expression to the possession of DRB1*04, *07 and *09 alleles is particularly intriguing. Only these DRB1 alleles are associated with expression of *HLA-DRB4*, encoding the DR53 superantigen⁵⁸. The reduced expression of *AOAH*, an enzyme that hydrolyses the potent innate immune stimulant lipopolysaccharide, in monocytes might be anticipated to pre-dispose towards inflammation. Whether the further association of *ARHGAP24*, encoding a protein involved in actin remodelling⁵⁹, a requirement for monocyte spreading and locomotion⁶⁰ is secondary to reduced *AOAH* expression will require further investigation. This study demonstrates that healthy individuals possess cell specific expression signatures attributable to *HLA* allele carriage, reflecting the overwhelming importance HLA status plays upon everyday immune interactions.

Comparative analysis of highly pure cell subsets has the potential to unearth added intricacy in the nature of eQTLs, highlighting that the majority act in a cell specific manner and many eQTLs will likely remain undiscovered if analysis focuses on heterogeneous tissues. This study adds strong evidence to support the concept that a large number of eQTL function in a

highly context specific manner *in vivo* and provide a plausible explanation for a degree of disease susceptibility.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We are very grateful to all the volunteers who participated in this study together with members of the Knight laboratory and Adrian Hill (University of Oxford) for their support. We thank Adam Auton for his assistance in the identification of probes containing SNPs with European MAF >0.01% using the 1000 Genome dataset and to John Broxholme for bioinformatic support and mapping of all probes to the reference sequence. We thank Greg Gibson (Georgia Institute of Technology), Adrian Hill and colleagues for critical reading of the manuscript and helpful suggestions. This work was supported by the Wellcome Trust (Grants 074318 [J.C.K.], 088891 [B.P.F.], and 075491/Z/04 [core facilities Wellcome Trust Centre for Human Genetics]), the European Research Council under the European Union's Seventh Framework Programme (FP7/2007-2013) / ERC Grant agreement no. 281824 (J.C.K.) and the NIHR Oxford Biomedical Research Centre.

REFERENCES

1. Cookson W, Liang L, Abecasis G, Moffatt M, Lathrop M. Mapping complex disease traits with global gene expression. *Nat Rev Genet.* 2009; 10:184–94. [PubMed: 19223927]
2. Gerrits A, et al. Expression quantitative trait loci are highly sensitive to cellular differentiation state. *PLoS Genet.* 2009; 5:e1000692. [PubMed: 19834560]
3. Dimas AS, et al. Common regulatory variation impacts gene expression in a cell type-dependent manner. *Science.* 2009; 325:1246–50. [PubMed: 19644074]
4. Nica AC, et al. The architecture of gene regulatory variation across multiple human tissues: the MuTHER study. *PLoS Genet.* 2011; 7:e1002003. [PubMed: 21304890]
5. Cheung VG, et al. Mapping determinants of human gene expression by regional and genome-wide association. *Nature.* 2005; 437:1365–9. [PubMed: 16251966]
6. Stranger BE, et al. Population genomics of human gene expression. *Nat Genet.* 2007; 39:1217–24. [PubMed: 17873874]
7. Emilsson V, et al. Genetics of gene expression and its effect on disease. *Nature.* 2008; 452:423–8. [PubMed: 18344981]
8. Schadt EE, et al. Mapping the genetic architecture of gene expression in human liver. *PLoS Biol.* 2008; 6:e107. [PubMed: 18462017]
9. Kwan T, et al. Tissue effect on genetic control of transcript isoform variation. *PLoS Genet.* 2009; 5:e1000608. [PubMed: 19680542]
10. Zeller T, et al. Genetics and beyond—the transcriptome of human monocytes and disease susceptibility. *PLoS ONE.* 2010; 5:e10693. [PubMed: 20502693]
11. Idaghdour Y, et al. Geographical genomics of human leukocyte gene expression variation in southern Morocco. *Nat Genet.* 2010; 42:62–7. [PubMed: 19966804]
12. Small KS, et al. Identification of an imprinted master trans regulator at the KLF14 locus related to multiple metabolic phenotypes. *Nat Genet.* 2011; 43:561–564. [PubMed: 21572415]
13. Lyons PA, et al. Microarray analysis of human leucocyte subsets: the advantages of positive selection and rapid purification. *BMC Genomics.* 2007; 8:64. [PubMed: 17338817]
14. Fehrmann RS, et al. Trans-eQTLs Reveal That Independent Genetic Variants Associated with a Complex Phenotype Converge on Intermediate Genes, with a Major Role for the HLA. *PLoS Genet.* 2011; 7:e1002197. [PubMed: 21829388]
15. Dixon AL, et al. A genome-wide association study of global gene expression. *Nat Genet.* 2007; 39:1202–7. [PubMed: 17873877]
16. Van Laer L, et al. Nonsyndromic hearing impairment is associated with a mutation in DFNA5. *Nat Genet.* 1998; 20:194–7. [PubMed: 9771715]

17. Akino K, et al. Identification of DFNA5 as a target of epigenetic inactivation in gastric cancer. *Cancer Sci.* 2007; 98:88–95. [PubMed: 17083569]
18. Schoggins JW, et al. A diverse range of gene products are effectors of the type I interferon antiviral response. *Nature.* 2011; 472:481–5. [PubMed: 21478870]
19. Xu H, Manivannan A, Crane I, Dawson R, Liversidge J. Critical but divergent roles for CD62L and CD44 in directing blood monocyte trafficking in vivo during inflammation. *Blood.* 2008; 112:1166–74. [PubMed: 18391078]
20. Landers JE, et al. Reduced expression of the Kinesin-Associated Protein 3 (KIFAP3) gene increases survival in sporadic amyotrophic lateral sclerosis. *Proc Natl Acad Sci U S A.* 2009; 106:9004–9. [PubMed: 19451621]
21. Benson V, Grobarova V, Richter J, Fiserova A. Glycosylation regulates NK cell-mediated effector function through PI3K pathway. *Int Immunol.* 2010; 22:167–77. [PubMed: 20089585]
22. Wen AY, Sakamoto KM, Miller LS. The role of the transcription factor CREB in immune function. *J Immunol.* 2010; 185:6413–9. [PubMed: 21084670]
23. Fischer U, et al. Cloning of a novel transcription factor-like gene amplified in human glioma including astrocytoma grade I. *Hum Mol Genet.* 1997; 6:1817–22. [PubMed: 9302258]
24. Birney E, et al. Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. *Nature.* 2007; 447:799–816. [PubMed: 17571346]
25. Hakonarson H, et al. A novel susceptibility locus for type 1 diabetes on Chr12q13 identified by a genome-wide association study. *Diabetes.* 2008; 57:1143–6. [PubMed: 18198356]
26. Nair RP, et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. *Nat Genet.* 2009; 41:199–204. [PubMed: 19169254]
27. Todd JA, et al. Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. *Nat Genet.* 2007; 39:857–64. [PubMed: 17554260]
28. WTCCC. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. *Nature.* 2007; 447:661–78. [PubMed: 17554300]
29. Plagnol V, Smyth DJ, Todd JA, Clayton DG. Statistical independence of the colocalized association signals for type 1 diabetes and RPS26 gene expression on chromosome 12q13. *Biostatistics.* 2009; 10:327–34. [PubMed: 19039033]
30. Koldobskiy MA, et al. p53-mediated apoptosis requires inositol hexakisphosphate kinase 2. *Proc Natl Acad Sci U S A.* 2010; 107:20947–51. [PubMed: 21078964]
31. Lawson BR, et al. Deficiency of the cyclin kinase inhibitor p21(WAF-1/CIP-1) promotes apoptosis of activated/memory T cells and inhibits spontaneous systemic autoimmunity. *J Exp Med.* 2004; 199:547–57. [PubMed: 14970181]
32. Kim K, et al. A regulatory SNP at position -899 in CDKN1A is associated with systemic lupus erythematosus and lupus nephritis. *Genes Immun.* 2009; 10:482–6. [PubMed: 19262578]
33. Zeggini E, et al. Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. *Nat Genet.* 2008; 40:638–45. [PubMed: 18372903]
34. Tomaru T, et al. Isolation and characterization of a transcriptional cofactor and its novel isoform that bind the deoxyribonucleic acid-binding domain of peroxisome proliferator-activated receptor-gamma. *Endocrinology.* 2006; 147:377–88. [PubMed: 16239304]
35. Hagen FS, et al. Expression and characterization of recombinant human acyloxyacyl hydrolase, a leukocyte enzyme that deacylates bacterial lipopolysaccharides. *Biochemistry.* 1991; 30:8415–23. [PubMed: 1883828]
36. Dilthey AT, Moutsianas L, Leslie S, McVean G. HLA*IMP--an integrated framework for imputing classical HLA alleles from SNP genotypes. *Bioinformatics.* 2011; 27:968–72. [PubMed: 21300701]
37. Leslie S, Donnelly P, McVean G. A statistical method for predicting classical HLA alleles from SNP data. *Am J Hum Genet.* 2008; 82:48–56. [PubMed: 18179884]
38. Lavelin I, Geiger B. Characterization of a novel GTPase-activating protein associated with focal adhesions and the actin cytoskeleton. *J Biol Chem.* 2005; 280:7178–85. [PubMed: 15611138]

39. Rioux JD, et al. Mapping of multiple susceptibility variants within the MHC region for 7 immune-mediated diseases. *Proc Natl Acad Sci U S A*. 2009; 106:18680–18685. [PubMed: 19846760]
40. Shiina T, Hosomichi K, Inoko H, Kulski JK. The HLA genomic loci map: expression, interaction, diversity and disease. *J Hum Genet*. 2009; 54:15–39. [PubMed: 19158813]
41. Hotfilder M, Baxendale S, Cross MA, Sablitzky F. Def-2, -3, -6 and -8, novel mouse genes differentially expressed in the haemopoietic system. *Br J Haematol*. 1999; 106:335–44. [PubMed: 10460589]
42. Vandiedonck C, et al. Pervasive haplotypic variation in the spliceo-transcriptome of the human major histocompatibility complex. *Genome Res*. 2011; 21:1042–54. [PubMed: 21628452]
43. Fellay J, et al. A whole-genome association study of major determinants for host control of HIV 1. *Science*. 2007; 317:944–7. [PubMed: 17641165]
44. Thomas R, et al. HLA-C cell surface expression and control of HIV/AIDS correlate with a variant upstream of HLA-C. *Nat Genet*. 2009; 41:1290–4. [PubMed: 19935663]
45. Limou S, et al. Genomewide association study of an AIDS-nonprogression cohort emphasizes the role played by HLA genes (ANRS Genomewide Association Study 02). *J Infect Dis*. 2009; 199:419–26. [PubMed: 19115949]
46. Liu Y, et al. A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. *PLoS Genet*. 2008; 4:e1000041. [PubMed: 18369459]
47. Strange A, et al. A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. *Nat Genet*. 2010; 42:985–990. [PubMed: 20953190]
48. Ho PY, et al. Investigating the role of the HLA-Cw*06 and HLA-DRB1 genes in susceptibility to psoriatic arthritis: comparison with psoriasis and undifferentiated inflammatory arthritis. *Ann Rheum Dis*. 2008; 67:677–82. [PubMed: 17728335]
49. Pereyra F, et al. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. *Science*. 2010; 330:1551–7. [PubMed: 21051598]
50. Nica AC, et al. Candidate causal regulatory effects by integration of expression QTLs with complex trait genetic associations. *PLoS Genet*. 2010; 6:e1000895. [PubMed: 20369022]
51. Barrett JC, et al. Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region. *Nat Genet*. 2009; 41:1330–4. [PubMed: 19915572]
52. Evans DM, et al. Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. *Nat Genet*. 2011; 43:761–7. [PubMed: 21743469]
53. Neznanov N, Neznanova L, Angres B, Gudkov AV. Serologically defined colon cancer antigen 3 is necessary for the presentation of TNF receptor 1 on cell surface. *DNA Cell Biol*. 2005; 24:777–85. [PubMed: 16332174]
54. Ruland J. CARD9 signaling in the innate immune response. *Ann N Y Acad Sci*. 2008; 1143:35–44. [PubMed: 19076343]
55. Andres AM, et al. Balancing selection maintains a form of ERAP2 that undergoes nonsense-mediated decay and affects antigen presentation. *PLoS Genet*. 2010; 6:e1001157. [PubMed: 20976248]
56. Elstak ED, et al. The munc13-4-rab27 complex is specifically required for tethering secretory lysosomes at the plasma membrane. *Blood*. 2011; 118:1570–8. [PubMed: 21693760]
57. Gray M, Miles K, Salter D, Gray D, Savill J. Apoptotic cells protect mice from autoimmune inflammation by the induction of regulatory B cells. *Proc Natl Acad Sci U S A*. 2007; 104:14080–5. [PubMed: 17715067]
58. Knowles RW, et al. Complexity of the supertypic HLA-DRw53 specificity: two distinct epitopes differentially expressed on one or all of the DR beta-chains depending on the HLA-DR allotype. *J Immunol*. 1986; 137:2618–26. [PubMed: 2428870]
59. Ohta Y, Hartwig JH, Stossel TP. FilGAP, a Rho- and ROCK-regulated GAP for Rac binds filamin A to control actin remodelling. *Nat Cell Biol*. 2006; 8:803–14. [PubMed: 16862148]
60. Stossel TP, et al. Filamins as integrators of cell mechanics and signalling. *Nat Rev Mol Cell Biol*. 2001; 2:138–45. [PubMed: 11252955]

61. Tedder TF, Isaacs CM. Isolation of cDNAs encoding the CD19 antigen of human and mouse B lymphocytes. A new member of the immunoglobulin superfamily. *J Immunol.* 1989; 143:712–7. [PubMed: 2472450]
62. Durbin RM, et al. A map of human genome variation from population-scale sequencing. *Nature.* 2010; 467:1061–73. [PubMed: 20981092]
63. Purcell S, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet.* 2007; 81:559–75. [PubMed: 17701901]
64. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. *Bioinformatics.* 2005; 21:263–5. [PubMed: 15297300]
65. Howie BN, Donnelly P, Marchini J. A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. *PLoS Genet.* 2009; 5:e1000529. [PubMed: 19543373]
66. Wickham, H. *ggplot2: Elegant Graphics for Data Analysis.* Springer; New York: 2009.
67. Pruim R, et al. LocusZoom: regional visualization of genome-wide association scan results. *Bioinformatics.* 2010; 26:2336–7. [PubMed: 20634204]




Figure 1. Shared and cell-specific cis and trans associations in B-cells and monocytes

(a) Venn diagrams illustrating the number of eSNPs unique to each cell subset and shared between datasets in cis (left panel) and in trans. B-cell data depicted in orange, monocyte in blue. (b) Circos plots for monocyte dataset (left panel) and B-cell dataset. From outside rim inwards: The outermost rim depicts a Manhattan plot for eQTLs from the respective dataset, the second rim depicts relative expression of genes, the third rim depicts an arbitrary selection of genes (constrained due to space) with significant trans-eQTLs ($p < 1 \times 10^{-11}$) and the innermost network depicts ‘spokes’ between nodal eSNPs and their trans-regulated genes. Such nodal eSNPs include rs10784774 which marks a monocyte specific master-regulatory region while rs10816519 identifies a B-cell specific master regulatory region. Red spokes: > 10 eSNPs from this locus map to the trans-eQTLs, blue spokes: > 1 and < 10 , grey spokes: 1 eSNP.




Figure 2. eSNPs shared between cell-types may lead to opposing directional effects on gene expression or associate with expression of different genes in a cell-specific manner
 (a) Using eSNPs shared between cell types the most significant eSNP per probe is plotted with the fold change in expression this eSNP causes in homozygous form between major and minor alleles (fold-change monocytes y- axis, B-cells x-axis). Whilst the majority of eSNPs shared between datasets cause the same directional change, there are examples of eSNPs that cause opposing directional changes in expression dependent upon cell-type. Only one eSNP is plotted per probe and only eSNPs with examples of >2 individuals homozygous in the minor allele with permuted $p < 0.001$ in both B-cells and monocyte datasets are annotated. (b) rs2223286 is associated with profound directional effects in the expression of *SELL* dependent upon genotype, with the minor C allele associated with increased expression of *SELL* in B-cells and reduced expression of *SELL* in monocytes ($p_{B-cell} = 4.6 \times 10^{-11}$, $p_{monocyte} = 1.1 \times 10^{-22}$). (c) rs738289 is an example of an eSNP that forms eQTL to differing genes dependent upon cell type. In B-cells this eSNP is strongly associated with the expression of *MGAT3* ($p_{B-cell} = 9.8 \times 10^{-26}$) with no association to *SYNGR1* expression; whilst in monocytes this eSNP is significantly associated with the expression of *SYNGR1* ($p_{monocyte} = 1.2 \times 10^{-17}$) with no association to *MGAT3* expression.




Figure 3. rs10784774 marks a monocyte specific cis-eSNP to *LYZ* and forms a monocyte specific master regulator of multiple genes including *CREB1*
 (a & b) rs10784774 is significantly associated with the expression of a probe mapping to the 3'UTR of *LYZ*, encoding lysozyme, in monocytes only ($p = 7.8 \times 10^{-8}$ B-cell N.S., $p_{\text{monocyte}} = 8.9 \times 10^{-78}$). (c) rs10784774 additionally forms an eSNP to 72 probes mapping across the genome, the most significantly associated being in the genes *CREB1* ($p = 2.0 \times 10^{-67}$), *DUSP19* ($p = 2.2 \times 10^{-59}$), and *RAB27A* ($p = 2.0 \times 10^{-57}$). (d) Manhattan plot demonstrating chromosomal location of all genes with probes mapping to rs10784774. The blue line represents 1.0×10^{-11} , red line 5.0×10^{-8} .




Figure 4. rs11171739, a SNP at 12q13.2 with strong autoimmune association forms B-cell specific trans-eQTL to 3 separate genes

(a) rs11171739 specifically associates with the B-cell trans expression of the genes *LAP3P2* ($p_{\text{B-cell}}=2.0 \times 10^{-52}$, $p_{\text{monocyte}}=1.7 \times 10^{-4}$), *IP6K2* ($p_{\text{B-cell}}=5.8 \times 10^{-15}$) and *PRIC285* ($p_{\text{B-cell}}=3.0 \times 10^{-10}$). (b) B-cell regional association plots of these genes demonstrating their expression by SNP marker across chromosome 12q13.2, a known autoimmune risk locus. (c) *LAP3P2* lies ~1kb 5' to *CDKN1A* and is denoted as a pseudogene. We observe a high degree of transcriptional activity in our RNA-seq data from CD19+ primary B-cells, and this is also seen in LCLs (GM12878)²⁴. This region is highly conserved amongst vertebrates.




Figure 5. Imputation of HLA status resolves cell-specific trans-associated gene expression to carriage of specific classical HLA alleles

(a) Regional association plots from monocyte and B-cell data demonstrating the monocyte specific trans association of the chromosome 7 gene *AOAH*, to the class II MHC gene *HLA-DRB1*. There is no association in B-cell dataset, whilst the peak eSNP from monocyte dataset is rs28366298 ($p_{\text{monocyte}}=1.6 \times 10^{-43}$). (b) Imputation of class II alleles to 2 digit resolution demonstrates that the C allele of rs28366298 is specific to DRB1 *04, *07 and *09 alleles and these alleles are associated with reduced *AOAH* expression. For clarity only homozygotes are plotted with two *AOAH* expression values per individual (corresponding to each DRB allele) are displayed. (c) The number of DRB1 *04/*07/*09 alleles carried by an individual is significantly associated with reduced expression of *AOAH* ($p_{\text{B-cell}} < 2.2 \times 10^{-16}$, one-way ANOVA) and increased expression of *ARHGAP24* ($p_{\text{monocyte}}=3.0 \times 10^{-14}$, one-way ANOVA). (d) Imputation of DQA1 status to 4 digits demonstrates that the G allele of rs35265698 is significantly associated with reduced expression of *DEF8* in both B-cells and monocytes ($p_{\text{B-cell}}=6.2 \times 10^{-13}$, $p_{\text{monocyte}}=9.0 \times 10^{-17}$). This allele is unique to DQA1*0301 as illustrated. For clarity only homozygotes of rs35265698 are plotted with two *DEF8* expression values per individual (corresponding to each DQA allele) displayed. (e) Higher numbers of DQA1*0301 alleles possessed by an individual is significantly associated with reduced *DEF8* expression ($p_{\text{B-cell}}=6.2 \times 10^{-13}$, $p_{\text{monocyte}} < 2.2 \times 10^{-16}$)




Figure 6. Cell specific cis-eQTL involving SNP markers associated with disease
 Genes showing significant cis-eQTL that involve SNPs reported at genome-wide significance ($p < 5 \times 10^{-8}$) in the Catalog of Published Genome-Wide Association Studies (www.genome.gov/GWA_studies) (accessed 10th September 2011) or proxy SNPs identified for these disease markers from the 1000 Genomes Project (CEU cohort, $r^2 > 0.8$) are shown. (a) List of genes with shared cis-eQTL/GWAS SNPs for UC, SLE and CD grouped by cell type and excluding HLA genes. Specific examples are described further in Supplementary Information. (b) Examples of genes showing eQTL involving SNPs associated with multiple GWAS traits.